

QIBA Diffusion-Weighted Imaging MR Biomarker Committee (BC) Call

Thursday, December 17, 2020 at 2 pm (CT)

Call Summary

Participants

Michael Boss, PhD (Co-chair)

Thomas Chenevert, PhD

Daniel Margolis, MD

RSNA

Joe Koudelik

Dariya Malyarenko, PhD (Co-chair)

Amita Shukla Dave, PhD

Nancy Obuchowski, PhD

Julie Lisiecki

Ishtiaq Bercha, MSc, MSEE

Carri Glide-Hurst, PhD

Savannah Partridge, PhD

Moderator: Dr. Boss

Review of Previous Call Summary

- The notes from the November 11, 2020 DWI BC t-con were approved as presented

QIBA Working Meeting Overview

- Dr. Boss summarized activities for each of the respective MR BCs at the QIBA Working Meeting on December 10th
- The overall theme from the meeting was advancement of QIBA Profiles through Technically Conformed (Stage 3), and promotion of QIBA in 2021, as well as an emphasis on making Profiles more user-friendly

General updates

- The DWI-MRI manuscript is nearly complete, though finishing touches are needed prior to submission to ECOG-ACRIN before the end of the year
- Adjustments to Dr. Guzmán's proposal for groundwork on head and neck squamous cell carcinoma may be needed
- Work continues offline for the VERDICT team

Profile Usability

- QIBA Leadership have asked BCs to make their Profiles more practical and ultimately implementable by technologists and clinical trialists; a top goal for the BC is to get the Profile into clinical trial (iCRO) use, and to make it more readable
- Feedback from Drs. O'Callaghan, Amaro, and Nascimento to be incorporated into the Profile to achieve technical confirmation for the Profile
- Suggestion to move some background detail, introductory language, discussion, and rationale into the appendices; the Profile will also be restructured to focus primarily on critical requirements for Profile conformance
- To clarify actors and their responsibilities and to provide an at-a-glance reference, checklist to be moved to a more prominent position – perhaps before the Executive Summary
 - Dr. Boss to discuss this reorganization with the Process Committee as there was concern that Profile users might disregard the appendices
 - Moving some of the main body text within the Profile along with disease-specific items into the appendices would decrease bulk and enhance readability
 - Dr. Malyarenko noted that parameters and other details are typically relegated to appendices for technologists and clinical trialists
- The performance assessment document could be made more concise
- Suggestion to limit literature review and task group formation details, and the following were recommended:
 - Adhere to the essentials
 - Include the minimum requirements necessary
 - Include clinical trial examples

- Drs. Glide-Hurst and Partridge have volunteered to take a fresh look at the Profile, shorten it, increase readability, color-highlight, and possibly rank sections that could be moved to appendices
 - Keeping in mind the primary use, or feasibility of implementation, will be key
 - The goal is to reach Claim Confirmed (Stage 4) in a clinical trial setting with a test-retest component
 - Other outside reviewers were encouraged to provide their perspectives
- Once at the Claim Confirmed stage, the team hopes to present the Profile to ECOG-ACRIN and other groups for clinical trial use
- Suggestion to submit an article to *Journal of Clinical Oncology* (JCO) to improve QIBA visibility and encourage Profile use
- Dr. Boss introduced the idea of “QIBA Guidance Documents,” which had been proposed by QIBA Leadership
 - These documents would be separate from the Profile and presented in a high-level summary format
- The group was reminded that the technical specification tables are needed for the claims and the checklists, and thus cannot be trimmed
- The target date for these new deliverables will be the first half of 2021
- Drs. Boss and Malyarenko to organize offline ad hoc calls to speed up the process for these efforts

Groundwork Proposals Request

- Dr. Boss asked BC members to consider including a budget line item and rationale for QIBA administrative support in any future pending grant/funding proposals
- Dr. Boss to follow up with QIBA Leadership regarding language to be used for any subcontracts

Next DWI-MR BC Call: Thursday, January 21, 2021 at 2 pm (CT)

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, **if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible.** Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries.